Guaifenesin is a mucoactive agent that provides symptomatic management of chest congestion and cough associated with acute upper respiratory tract infections (URTIs). This accredited program reviews the purpose of mucus in a healthy respiratory system, and what happens when hypersecretion or mucus dysfunction occurs. Guaifenesin increases hydration of airway mucus, increases the volume of bronchial secretions and decreases mucus viscosity, which enhances clearance by promoting more effective expectoration.
Two case studies highlight key features of guaifenesin including indications, dosing and frequency. The impact of COVID-19 on counseling customers with respiratory symptoms is also addressed.
This program has received an unrestricted educational grant or in-kind support from RB Health (Canada) Inc.